Cargando…
Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
Epithelial ovarian carcinoma (EOC) is the most lethal gynecological malignancy. Herein, we sought to determine the efficacy of phosphoinositide 3-kinase (PI3K)/Akt inhibition using three AZD compounds in a NOD-SCID xenograft mouse model and Akt regulation in a panel of eight ovarian cancer cell line...
Autores principales: | Wu, Yi-Hui, Huang, Yu-Fang, Chen, Chien-Chin, Huang, Chia-Yen, Chou, Cheng-Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063971/ https://www.ncbi.nlm.nih.gov/pubmed/32194423 http://dx.doi.org/10.3389/fphar.2020.00206 |
Ejemplares similares
-
Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma
por: Xia, Zhong-Kun, et al.
Publicado: (2021) -
Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression
por: Wu, Yi-Hui, et al.
Publicado: (2019) -
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022) -
Cinnamaldehyde Suppressed EGF-Induced EMT Process and Inhibits Ovarian Cancer Progression Through PI3K/AKT Pathway
por: Wang, Yue, et al.
Publicado: (2022) -
Ligustilide Attenuates Ischemia Reperfusion-Induced Hippocampal Neuronal Apoptosis via Activating the PI3K/Akt Pathway
por: Wu, Qian, et al.
Publicado: (2020)